NCT04117321 Mother-infant Microbiota Transmission and Its Link to the Health of the Baby
| NCT ID | NCT04117321 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Gut Microbiome |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2019-09-23 |
| Primary Completion | 2026-10-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2019-09-23 with a primary completion date of 2026-10-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The human intestinal tract harbors a diverse and complex microbial community, known as gut microbiota, which is critical in sustaining physiology, metabolism, nutrition and immune function. Dysbiosis of gut microbiota has been linked with obesity, hyperglycemia, hyperlipidemia, inflammatory bowel disease and other chronic inflammatory diseases. Gut microbiota is affected by host genetic markup, diet and life style; and therefore varied by human races and geographical locations. The development of gut microbiota starts before birth. The infant's microbiome can impact on human health in later life. The microbiome of pregnant women are associated with early-life microbiota of their offspring as well as growth, neurodevelopment and the development of allergic and neurocognitive disorders. Early childhood, when the microbiota is less mature and more malleable, is a golden age for microbiota manipulation to prevent disease. Studying microbiota at this golden age also allow us to dissect the development of a faulty microbiota and identify therapeutic targets to reverse it and cure diseases that are already developed.
Eligibility Criteria
Pregnant women Inclusion Criteria: 1. Being pregnant 2. Plan to give birth in local hospital 3. Competent to provide informed consent (no mental illness or dementia, etc. that will hinder their ability to undertake informed consent) 4. Plan to stay in the same local area for at least 7 years post-delivery Exclusion Criteria: No New Born Baby Inclusion Criteria 1. Be a new born baby of an enrolled pregnant woman 2. One of the parents or legal guardian is competent to provide informed consent (no mental illness or dementia, etc. that will hinder their ability to undertake informed consent) Exclusion Criteria: No Father of new born baby Inclusion Criteria 1. Biological father of an enrolled new born baby 2. Competent to provide informed consent (no mental illness or dementia, etc. that will hinder their ability to undertake informed consent) Exclusion Criteria: No
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04117321 clinical trial?
This trial is open to participants of all sexes, studying Gut Microbiome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04117321 currently recruiting?
Yes, NCT04117321 is actively recruiting participants. Contact the research team at jessicaching@cuhk.edu.hk for enrollment information.
Where is the NCT04117321 trial being conducted?
This trial is being conducted at Hong Kong, China.
Who is sponsoring the NCT04117321 clinical trial?
NCT04117321 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 20,000 participants.